Skip to main content
YUNGJIN PHARM. CO., LTD logo

YUNGJIN PHARM. CO., LTD — Investor Relations & Filings

Ticker · 003520 ISIN · KR7003520004 KO Manufacturing
Open in API
Filings indexed 193 across all filing types
Latest filing 2026-05-28 Governance Information
Country KR South Korea
Listing KO 003520

About YUNGJIN PHARM. CO., LTD

https://eng.yungjin.co.kr/

Yungjin Pharm. Co., Ltd. is a pharmaceutical company engaged in the research, development, manufacturing, and sale of pharmaceutical products for domestic and international markets. The company's portfolio includes a range of prescription drugs, with a focus on areas such as cephalosporin antibiotics and antipsychotic medications. Yungjin Pharm is actively involved in advancing its R&D pipeline, which includes collaborative research for treatments of rare conditions like mitochondrial diseases. Leveraging extensive drug production expertise and R&D capabilities, the company operates as a key affiliate within the KT&G Group's bio/pharmaceutical business.

Recent filings

Filing Released Lang Actions
기업지배구조보고서공시
Governance Information Classification · 90% confidence The document is a detailed corporate governance report (“기업지배구조보고서 신고서”) covering governance policies, board composition, compliance with core governance indicators, shareholder meeting processes, and ESG governance recognitions. It contains substantive governance content rather than merely announcing the report’s publication. This aligns with the Governance Information category.
2026-05-28 Korean
분기보고서 (2026.03)
Interim / Quarterly Report Classification · 99% confidence The document is titled “분기보고서” for the 65th fiscal period covering January 1 to March 31, 2026. It contains comprehensive financial statements, segment information, business overviews, management’s discussion, production, sales data, and notes. It is clearly an interim/quarterly report rather than a brief announcement or link to another report. Therefore, it matches the definition of an Interim / Quarterly Report (Code: IR). Q1 2026
2026-05-15 Korean
영업(잠정)실적(공정공시)
Earnings Release Classification · 95% confidence The document is titled '영진약품/영업(잠정)실적(공정공시)' which translates to 'Yeongjin Pharmaceutical / Sales (Provisional) Performance (Fair Disclosure)'. It provides provisional financial results for the period 2026-01-01 to 2026-03-31, including sales, operating profit, and net income figures. The document explicitly states that these are provisional figures not yet audited and may change upon finalization. It also mentions that the data will be presented at a KT&G investor presentation event. The document length is 2119 characters, which is relatively short and mainly provides summary provisional financial data rather than a full detailed financial report. This fits the profile of an Earnings Release (ER), which is an initial announcement of quarterly or periodical financial results with key highlights only. It is not a full Interim Report (IR) because it lacks comprehensive financial statements and detailed analysis. It is not a Report Publication Announcement (RPA) because it contains actual provisional financial data, not just a notice of report availability. Therefore, the best classification is Earnings Release (ER). Q1 2026
2026-05-06 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an official report of the results of a General Meeting of Shareholders (정기주주총회결과), detailing the approval of financial statements, dividend decisions, and the election of board members and auditors. This falls directly under the category of Declaration of Voting Results & Voting Rights Announcements.
2026-03-20 Korean
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Board/Management Information Classification · 100% confidence The document is a formal regulatory filing submitted to the Financial Supervisory Service/Korea Exchange regarding the appointment, dismissal, or resignation of outside directors (사외이사). It details specific names, appointment dates, and reasons for departure (e.g., expiration of term, voluntary resignation). This falls under the category of Board/Management Information, specifically concerning changes in the board composition.
2026-03-20 Korean
사업보고서 (2025.12)
Audit Report / Information Classification · 97% confidence The document is a comprehensive financial report for the fiscal year 2025, including the independent auditor's report, balance sheet, income statement, statement of changes in equity, cash flow statement, and detailed notes. It is titled '감사보고서' (Audit Report) and contains the full financial statements for the company '영진약품(주)'. While it includes an audit report, the presence of the full financial statements and notes for the annual period classifies it as an Annual Report (10-K) in the context of standard financial reporting filings. FY 2025
2026-03-12 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.